Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
John C. Byrd(The Ohio State University), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Richard R. Furman(Cornell University), Julio Delgado(Departament de Salut), Florence Cymbalista(Hôpital Avicenne), Steven Coutré(Georgetown University), Fong Clow(Pharmacyclics (United States)), Jennifer R. Brown(Dana-Farber Cancer Institute), Adrian Bloor(The Christie NHS Foundation Trust), Devinder Gill(Princess Alexandra Hospital), Christopher Pocock(East Kent Hospitals University NHS Foundation Trust), Constantine S. Tam(The Alfred Hospital), Jesse McGreivy(Pharmacyclics (United States)), Thomas J. Kipps(University of California San Diego), Marco Montillo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Maria Fardis(Pharmacyclics (United States)), Paul M. Barr(University of Rochester Medical Center), Carol Moreno(Hospital de Sant Pau), Claire Dearden(Royal Marsden Hospital), Anna Schuh(University of Oxford), Jacqueline C. Barrientos(Mount Sinai Medical Center), Patrick Thornton(Beaumont Hospital), Stephen J. Schuster(Hospital of the University of Pennsylvania), Danelle F. James(Pharmacyclics (United States)), Sven de Vos(University of California, Los Angeles), Nishitha Reddy(Vanderbilt University), Tadeusz Robak(Medical University of Lodz), Stephen P. Mulligan(Royal North Shore Hospital), Federico Caligaris‐Cappio(Vita-Salute San Raffaele University), Alvina D. Chu(AbbVie (United States)), Ulrich Jaeger(Medical University of Vienna), Neil E. Kay(Mayo Clinic), Jeffrey J. Jones(The Ohio State University), Susan O’Brien(University of California, Irvine)
Cited by 1,615
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k